Key facts
- The FDA has approved Moderna's mRNA-based flu vaccine, mFlusiva.
- mFlusiva is the first flu vaccine to use mRNA technology.
- The vaccine is approved for adults aged 50 and older.
- The approval followed a dispute over the application.
- mRNA technology allows for faster manufacturing.
- This technology is also used for COVID-19 vaccines.
- The vaccine offers a new option for influenza prevention.
The Food and Drug Administration (FDA) has approved Moderna's mRNA-based flu vaccine, named mFlusiva, for adults aged 50 and older. This approval signifies a significant advancement as mFlusiva is the first flu vaccine to utilize messenger RNA (mRNA) technology, which was previously employed for COVID-19 vaccines. The development offers a new avenue for influenza prevention.
The approval comes after a period of dispute concerning Moderna's application. The mRNA technology employed in mFlusiva is noted for its potential to be manufactured more rapidly compared to traditional flu vaccines. This characteristic is particularly advantageous in combating evolving influenza strains, which require timely vaccine updates.
The FDA's decision provides an alternative to existing flu vaccination methods, leveraging the same platform that proved effective during the COVID-19 pandemic. The focus on adults aged 50 and older suggests an initial target demographic for this novel vaccine.